Researchers at Houston Methodist have developed an artificial intelligence (AI) software that reliably interprets mammograms, assisting doctors with a quick and accurate prediction of breast cancer risk. According to a new study published in Cancer (early online Aug. 29), the computer software intuitively translates patient charts into diagnostic information at 30 times human speed and with 99 percent accuracy.
“This software intelligently reviews millions of records in a short amount of time, enabling us to determine breast cancer risk more efficiently using a patient’s mammogram. This has the potential to decrease unnecessary biopsies,” says Stephen T. Wong, Ph.D., P.E., chair of the Department of Systems Medicine and Bioengineering at Houston Methodist Research Institute.
The team led by Wong and Jenny C. Chang, M.D., director of the Houston Methodist Cancer Center used the AI software to evaluate mammograms and pathology reports of 500 breast cancer patients. The software scanned patient charts, collected diagnostic features and correlated mammogram findings with breast cancer subtype. Clinicians used results, like the expression of tumor proteins, to accurately predict each patient’s probability of breast cancer diagnosis.
In the United States, 12.1 million mammograms are performed annually, according to the Centers for Disease Control and Prevention (CDC). Fifty percent yield false positive results, according to the American Cancer Society (ACS), resulting in one in every two healthy women told they have cancer.
Currently, when mammograms fall into the suspicious category, a broad range of 3 to 95 percent cancer risk, patients are recommended for biopsies.
Over 1.6 million breast biopsies are performed annually nationwide, and about 20 percent are unnecessarily performed due to false-positive mammogram results of cancer free breasts, estimates the ACS.
The Houston Methodist team hopes this artificial intelligence software will help physicians better define the percent risk requiring a biopsy, equipping doctors with a tool to decrease unnecessary breast biopsies.
Manual review of 50 charts took two clinicians 50-70 hours. AI reviewed 500 charts in a few hours, saving over 500 physician hours.
“Accurate review of this many charts would be practically impossible without AI,” says Wong.
The Latest on: Breast cancer risk prediction
via Google News
The Latest on: Breast cancer risk prediction
- US Patent Office Grants Key Risk Test Patenton June 18, 2020 at 9:06 am
US 10,683,549, Methods for assessing risk of developing breast cancer.Filed provisional patent for its COVID-19 Severity Risk Test, 2020901739 –.
- Jane Lowe Meisel, MD, on the Breast Cancer Advances in ASCO's Clinical Cancer Advances Reporton June 16, 2020 at 1:02 pm
In the following interview, the report's breast cancer specialty editor, Jane Lowe Meisel, MD, of Emory University Winship Cancer Institute in Atlanta, elaborated on the advances and discussed future ...
- Mammographic Density, Breast Cancer Risk and Risk Predictionon June 11, 2020 at 5:00 pm
BI-RADS = Breast Imaging Reporting and Data System; CI = confidence interval; Ref = reference; RR = relative risk. Visual classification of the mammographic image into four categories based on ...
- Artificial intelligence, probabilistic modeling can improve prediction of survival in cancer patientson June 11, 2020 at 8:55 am
Improving the prediction of survival indicators in patients with breast cancer using tools ... a prediction of indicators on survival and risk of cancer mortality -and other causes- of each ...
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Canceron June 10, 2020 at 5:00 pm
estrogen-receptor–positive breast cancer who had been treated with tamoxifen. The difference in the risk of distant recurrence between patients with low recurrence scores and those with high ...
- Mammographic Density, Breast Cancer Risk and Risk Predictionon June 1, 2020 at 5:00 pm
Given the evidence that the pathogenesis of breast cancer likely begins early in life, prior to the age at which mammography is recommended, additional risk prediction approaches are likely ...
- Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast canceron May 29, 2020 at 4:08 am
with Oncotype DX in the TransATAC cohort,” shows that StemPrintER Outperforms Oncotype DX in 10-year risk prediction in more than 800 ER+/HER2- postmenopausal breast cancer patients in the ...
- Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast canceron May 28, 2020 at 11:00 pm
with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer patients,” demonstrates that the next-generation StemPrintER Risk Score (SPARE ...
- Shivom Partnership With Genetic Technologies Will Enable Better Cancer Prediction and Prevention Through Mass Genomic Data Analysison May 25, 2020 at 5:00 pm
that is expected to accelerate the prediction of cancer for millions of individuals worldwide. GTG, whose lead product is BREVAGenplus® - a clinically validated risk assessment test for non-hereditary ...
- Bone density predicts risk of canceron October 7, 2018 at 3:34 pm
They found that a risk prediction equation that includes breast density measurements accurately predicts breast cancer risk in some women, but is less accurate in other women. The American Cancer ...
via Bing News